Skip to main content
Equibles
RXRX logo

RXRX · Recursion Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio

Track RXRX — free

Use RXRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RXRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.70 +0.12 (+3.35%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$1.98B
Shares
535.34M
Volume · Oct 23 19.08M Avg daily vol (3M) 21.75M

Recursion Pharmaceuticals, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Recursion Pharmaceuticals, Inc. (RXRX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Conference
Investor event
2026-09-15
Recursion Pharmaceuticals, Inc. (RXRX) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2026 Earnings Call
Revenue
$7.67M
▼ 60.1% YoY
Diluted EPS
$-0.25
Gross margin
-49.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Recursion Pharmaceuticals, Inc. (RXRX) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-12
Recursion Pharmaceuticals, Inc. (RXRX) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Recursion Pharmaceuticals, Inc. (RXRX) Q1 2026 Earnings Call Transcript
Confident tone AI-native product engine and platform Wholly owned clinical pipeline Clinical proof points and catalysts
Revenue
$6.47M
▼ 56.1% YoY
Diluted EPS
$-0.22
Gross margin
-93.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Recursion Pharmaceuticals, Inc. (RXRX) Q4 2025 Earnings Call Transcript
Confident tone Upcoming catalysts and FDA engagement Sanofi partnership and milestones Clinical pipeline and FAP proof of concept
Revenue
$35.54M*
▲ 681.7% YoY
Gross margin
59.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call Transcript
Confident tone Roche/Genentech partnership & milestones CEO leadership transition Partnership strategy (incl. Sanofi, new deals)
Revenue
$5.17M
▼ 80.2% YoY
Diluted EPS
$-0.36
Gross margin
-183.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript
Confident tone Internal pipeline programs Recursion OS platform Boltz-2 partnership and open source
Revenue
$19.22M
▲ 33.3% YoY
Diluted EPS
$-0.41
Gross margin
-4.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript
Positive tone Discontinued Programs Pharma Partnerships Rare Disease / FAP Program
Revenue
$14.74M
▲ 6.9% YoY
Diluted EPS
$-0.50
Gross margin
-48.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-28
Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript
Confident tone TechBio platform and AI/ML capabilities Pharma partnerships and milestones NIH funding concerns and ecosystem risk
Revenue
$4.55M*
▼ 58.3% YoY
Gross margin
-181.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q2
2024-08-08
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript
Confident tone Pharma partnerships Pipeline and clinical readouts Exscientia combination
Revenue
$14.42M
▲ 30.9% YoY
Diluted EPS
$-0.40
Gross margin
36.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Recursion Pharmaceuticals, Inc. (RXRX) Q1 2024 Earnings Call Transcript
Confident tone Industry outlook and competition Strategic partnerships and collaborations Platform and data layers
Revenue
$13.79M
▲ 13.7% YoY
Diluted EPS
$-0.39
Gross margin
19.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Recursion Pharmaceuticals, Inc. (RXRX) Q4 2023 Earnings Call Transcript
Confident tone Partnerships TechBio platform and Recursion OS Pipeline and clinical milestones
Revenue
$10.89M*
▼ 20.4% YoY
Gross margin
9.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q1
2023-05-08
Recursion Pharmaceuticals, Inc. (RXRX) Q1 2023 Earnings Call
Revenue
$12.13M
▲ 127.5% YoY
Diluted EPS
$-0.34
Gross margin
-2.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-27
Recursion Pharmaceuticals, Inc. (RXRX) Q4 2022 Earnings Call
Revenue
$13.68M*
▲ 439.9% YoY
Gross margin
20.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–15 of 15 webcasts
Key facts CIK 1601830 CUSIP 75629V104 13F (30d) 51 filings 51 filers Visit website Investor relations